Does anyone think that it could be a problem that SM6 is currently completely reliant on the PERC6 method of manufacture and this technology is owned by J and J (Crucell) who is currently developing Daratumumab?
Why would a large pharma take on the compound if it potentially cant be made using another method and the current method is controlled by another large pharma with a directly competing compound?
I think this is why the trial is so small and took so long to progress. Amgen wouldn't risk much until an alternate cell manufacture system is available. I'm not sure on licensing requirements at Crucell, but I'm sure they can do what they please.
If this area is as competitive as the money that gets thrown around suggests it may be a valid theory for such a low market cap.
I know its impossible to value small bios especially on the asx, but think PAB has been hammered for a reason.
Daratumumab seems to be progressing well.
PAB Price at posting:
2.0¢ Sentiment: None Disclosure: Held
